3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 3
10
Phase NA
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
6
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Prostatic Neoplasms
1
Plasmacytoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Melanoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Immunoglobulin Light-chain Amyloidosis
1
Carcinoma, Renal Cell
1
Amyloidosis
1
Interventions
Melphalan
16
Dexamethasone
15
Bortezomib
11
Peripheral Blood Stem Cell Transplantation
9
Lenalidomide
9
fludarabine phosphate
8
Calcium Dobesilate
7
pomalidomide
5
fludarabine
5
Busulfan
5
carfilzomib
4
Radiotherapy
4
Prednisone
4
Cyclophosphamide
4
liposomal doxorubicin
3
daratumumab
3
Tacrolimus
3
Mycophenolic Acid
3
Methotrexate
3
Filgrastim
3
Cyclosporine
3
Arsenic Trioxide
3
Alemtuzumab
3
samarium Sm-153 lexidronam
2
holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
2
Whole-Body Irradiation
2
Surveys and Questionnaires
2
Pneumococcal Vaccines
2
Granulocyte Colony-Stimulating Factor
2
Bendamustine Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms, Plasma Cell
×
Thalidomide
×
Clear all
NCT00406978
2016-05-10
MPTD
University of Turin, Italy
Phase 1/2
Completed
24 enrolled